Antidotes

Antidotes

 

2,3-Dimercapto-1-propanesulfonic acid sodium,4076-02-2
2,3-Dimercapto-1-propanesulfonic acid sodium
2,3-Dimercapto-1-propanesulfonic acid sodium,4076-02-2
CAS
4076-02-2
Molecular Formula
C3H7O3S3.Na
Molecular Weight
210.2733
Systematic Name
1-Propanesulfonic acid, 2,3-dimercapto-, monosodium salt /DMPS 
Assay
CP2010
Certificate of analysis
2,3-Dimercapto-1-propanesulfonic acid sodium,4076-02-2
View via PDF file
2,3-Dimercapto-1-propanesulfonic acid sodium,4076-02-2
Specification
Items
Specification
Test result
Appearance
White or off-white crystalline powder,tasteless, with onion-like odor and moisture regain
Complies
Solubility
Readily soluble in water, insoluble in ethanol,chloroform and ethyl ester.
Complies
Solution color
Not more than Brown 1#
Complies
Clarity of Solution
Not more than 1#
Complies
Identification
Meet the requirement
Complies
pH(25℃)
3.5 to 5.0
4.4
Loss on drying
Not more than 1.0%
0.2%
Alcohol
Not more than 0.1%
0.007%
Reside on ignition
32.5% to 34.5%
34.2%
Heavy Metal
Not more than 10ppm
Complies
Related substance
Not more than 5.0%
Complies
Count of bacteria
Bacillus<1000 Entries/g
Complies
Mildew<100 Entries/g
Complies
Microzyme <100 Entries/g
Complies
Assay
>98.0%
98.5%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Antidotes
DMPS [HOT]
DMSA [HOT]
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lanos' Pharmaceutical Co.,LTD ’s product(2,3-Dimercapto-1-propanesulfonic acid sodium,4076-02-2,CP2010).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.